Sai Parenterals Q4 and FY26: Building a larger CDMO platform through Noumed and a heavy capex cycle

Sai Parenterals ended FY26 as a newly listed company with a meaningfully larger consolidated footprint after acquiring a majority stake in Noumed Pharmaceuticals in Australia. The year included a step change in reported scale at the group level and a clear message from management: FY27 is positioned as an execution and investment year, while FY28 is expected to show the financial impact of commissioning projects and deeper vertical integration.

In Q4FY26, the first full quarter of Noumed consolidation, the company reported consolidated revenue of 198 crore, EBITDA of 29 crore, and PAT of 13 crore. For FY26, consolidated revenue from operations was 381 crore, with EBITDA of 47 crore and PAT of 14 crore. The presentation also highlighted that standalone performance remained strong, with FY26 standalone revenue from operations at 162 crore, EBITDA at 33 crore, and PAT at 17 crore.

FY26 performance: standalone strength and a partial-year consolidated base

The reported consolidated numbers reflect only part-year inclusion of Noumed, as the acquisition was completed on November 12, 2025 and consolidated from that date. This matters because FY26 consolidated profitability and margins combine two different operating profiles across time periods. The presentation shows FY26 consolidated EBITDA margin at 12 percent and PAT margin at 4 percent, while Q4FY26 margins were higher.

Management framed the year as transformational, combining public listing with an international platform in Australia and New Zealand. The operating narrative focused on three complementary engines: a growing CDMO export business, a regulated market platform in Australia and New Zealand through Noumed, and a domestic branded formulations business as the base.

Financial summary

Strategy and the Noumed logic: dossiers, access and vertical integration

The acquisition of Noumed is central to the company’s next phase. In the investor presentation, Sai Parenterals positioned itself as a preferred CDMO partner for customers in regulated and semi-regulated markets, with a dossier and registration base that supports faster expansion.

The presentation stated a portfolio of 302 complex products and highlighted 599 approved product registrations in regulated markets, including 456 approvals with TGA Australia and 143 approvals in other countries. It also stated that FY26 added 93 dossiers, including 88 regulated and emerging market filings and five TGA Australia dossiers through Noumed. In addition, 67 dossiers were stated to be under development, which management said are expected to be commercialized during FY27 and FY28.

In management commentary, the strategic value of Noumed was described in two layers. The first is commercial access. Noumed has exclusive long-term supply agreements with Australian pharmacy chains, and the company highlighted exposure to Australia and New Zealand markets with both prescription and OTC products.

The second is operational leverage through vertical integration. Management stated that Noumed currently outsources a significant portion of manufacturing requirements, and the group intends to progressively internalize a meaningful portion of production as the Australian manufacturing facility becomes operational. In response to an investor question on margin expansion, management explicitly linked the targeted improvement to shifting manufacturing from external CMOs to Sai Parenterals’ own facilities, and later to Noumed’s own Australian manufacturing base.

Capex cycle and commissioning timelines: heavy FY27 execution focus

The company is executing a broad expansion and upgradation plan across India and Australia, supported by IPO proceeds and additional funding at the subsidiary level.

The presentation table outlined planned capacity changes and timelines. Unit I injectables capacity is planned to increase from 42 million units to 78 million units, with post-upgradation accreditations including EU-GMP, WHO-GMP and PIC/S, targeted for completion in January 2027. Unit II injectables is planned to expand from 15 million units to 21 million units with similar post-upgradation accreditations, also targeted for January 2027. Unit IV is planned for EU-GMP upgradation with a January 2027 target date.

Unit III in India, described as a TGA Australia approved manufacturing facility, is planned to expand capacity from 240 million units to 451 million units, with expected completion in October 2026. The presentation also disclosed a dedicated R&D facility capex of 18 crore with a July 2027 completion target.

For Australia, the Adelaide manufacturing facility under Noumed, focused on tablets, liquid orals and nasal sprays, was described as on track for completion in Q4FY27. The capex table disclosed an AUD 53 million capex plan and noted that an AUD 20 million grant has already been disbursed by the Australian Government.

On the earnings call, the CFO described the overall growth capex program as 440 crore. He stated that 111 crore is being deployed for capacity expansion and EU-GMP upgrades in India and 18 crore for the R&D center, both funded through IPO proceeds. For the Australian facility, he stated the planned capex is about AUD 53 million, with the grant already received and the balance funded through a mix of debt and internal accruals, and that AUD 40 million had been invested to date.

Management repeatedly emphasized that these projects are not expected to contribute to FY27 financial performance. They stated commissioning is expected towards the end of FY27, making FY28 the period where expanded capacities, regulatory upgrades, and vertical integration benefits are expected to begin showing in revenues and margins.

FY27 guidance and what management asked investors to track

The clearest forward-looking statement in the call was explicit numeric guidance: management said it is targeting revenue of 750 crore in FY27 with EBITDA margin in the range of 17 percent. They described FY27 as supported by execution of existing long-term contracts, commercialization of new dossiers, increasing contribution from Noumed, and continued momentum in the CDMO export business.

The call also included balance sheet and funding commentary. The CFO stated that as of March 2026, total debt was about 319 crore, comprising 90 crore of long-term borrowings and 229 crore of short-term borrowings. He added that FY27 is expected to be the peak year of debt as capex completes, with debt expected to decline from FY28 onwards as assets begin contributing to earnings and cash flows.

The company also disclosed the intended use of IPO gross proceeds of 285 crore in the presentation. This included 111 crore for capacity expansion and upgradation, 18 crore for a new R&D centre, 14 crore for repayment or prepayment of certain institutional borrowings, 33 crore for working capital, 36 crore towards repayment of bridge and term loan related to the Noumed acquisition, 45 crore for general corporate purposes, and 28 crore for issue expenses.

Closing takeaways

Sai Parenterals’ FY26 narrative is anchored in a larger consolidated platform after Noumed, and a strong standalone base that management says is benefiting from CDMO momentum. The near-term is defined by commissioning and integration execution rather than immediate benefits from new assets.

The key signals in the documents are explicit. Management provided FY27 guidance of 750 crore revenue and about 17 percent EBITDA margin. It also stated that most capex projects will be commissioned towards the end of FY27 and are expected to contribute meaningfully from FY28.

For investors, the story will likely be shaped by progress on EU-GMP upgrades in India, timelines and commissioning of the Adelaide facility, and the ability to translate the dossier pipeline and long-term supply agreements into repeatable growth with improving margins as vertical integration increases.